Evidence map›Paper›PMID 20976051›Full record

Trial reportPloS one2010

Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.

Joaniter Nankabirwa, Bonnie Cundill, Sian Clarke, Narcis Kabatereine, Philip J Rosenthal, Grant Dorsey, Simon Brooker, Sarah G Staedke

3 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00852371 phase3completednot on this map

IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2008 to 2008Enrolled780ConditionsMalaria, Intermittent Preventive TreatmentArmssulfadoxine-pyrimethamine, amodiaquine + sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, Placebo
NCT02009215 phase4completednot on this mapstarted 2014, after this paper: background citation

'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2014 to 2015Enrolled10,746ConditionsMalariaArmsDihydroartemisinin-piperaquine (DP)
NCT04660110 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of the Household-level Impact of a Single Round of Intermittent Preventive Treatment of Malaria in Schoolchildren: A Randomized Study

TypeinterventionalSponsorMakerere UniversityRan2021 to 2021Enrolled1,500ConditionsMalariaArmsIPT with Dihydroartemisinin Piperaquine
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mass drug administration for malaria.The Cochrane database of systematic reviews · 2013
    Pooled it
  4. Trial
  5. Trial
  6. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Joaniter NankabirwaUganda Malaria Surveillance Project, Kampala, Uganda.
Bonnie Cundill
Sian Clarke
Narcis Kabatereine
Philip J Rosenthal
Grant Dorsey
Simon Brooker
Sarah G Staedke
London School of Hygiene & Tropical Medicine · GBMalaria Consortium · UGKenya Medical Research Institute · KEMinistry of Health · UGSan Francisco General Hospital · USUniversity of California, San Francisco · US

Funding

Wellcome Trust 084933
6 · The paper itself

Abstract

backgroundIntermittent preventive treatment (IPT) is a promising malaria control strategy; however, the optimal regimen remains unclear. We conducted a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of a single course of sulfadoxine-pyrimethamine (SP), amodiaquine + SP (AQ+SP) or dihydroartemisinin-piperaquine (DP) among schoolchildren to inform IPT.

methodsAsymptomatic girls aged 8 to 12 years and boys aged 8 to 14 years enrolled in two primary schools in Tororo, Uganda were randomized to receive one of the study regimens or placebo, regardless of presence of parasitemia at enrollment, and followed for 42 days. The primary outcome was risk of parasitemia at 42 days. Survival analysis was used to assess differences between regimens.

resultsOf 780 enrolled participants, 769 (98.6%) completed follow-up and were assigned a treatment outcome. The risk of parasitemia at 42 days varied significantly between DP (11.7% [95% confidence interval (CI): 7.9, 17.1]), AQ+SP (44.3% [37.6, 51.5]), and SP (79.7% [95% CI: 73.6, 85.2], p<0.001). The risk of parasitemia in SP-treated children was no different than in those receiving placebo (84.6% [95% CI: 79.1, 89.3], p = 0.22). No serious adverse events occurred, but AQ+SP was associated with increased risk of vomiting compared to placebo (13.0% [95% CI: 9.1, 18.5] vs. 4.7% [95% CI: 2.5, 8.8], respectively, p = 0.003).

conclusionsDP was the most efficacious and well-tolerated regimen tested, although AQ+SP appears to be a suitable alternative for IPT in schoolchildren. Use of SP for IPT may not be appropriate in areas with high-level SP resistance in Africa.

trial registrationClinicalTrials.gov NCT00852371.

Indexed as

AdolescentAntimalarialsChildFemaleHumansMalariaMalePlacebosUgandaAntimalarialsPlacebos

Identifiers

PMID20976051
PMCPMC2957410
OpenAlexW2036003931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.